Walgreens Boots Alliance Management

Management criteria checks 1/4

Walgreens Boots Alliance's CEO is Tim Wentworth, appointed in Oct 2023, has a tenure of less than a year. directly owns 0.068% of the company’s shares, worth $9.19M. The average tenure of the management team and the board of directors is 0.9 years and 3.7 years respectively.

Key information

Tim Wentworth

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.07%
Management average tenure	less than a year
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO

Tim Wentworth (64 yo)

less than a year

Tenure

Mr. Timothy C. Wentworth, also known as Tim, served as Director of Ushur, Inc. since February 2022. He served as the Chief Executive Officer of Evernorth at Evernorth Health, Inc. (formerly known as Expres...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stefano Pessina	Executive Chairman of the Board	12.2yrs	US$7.57m	0.076% $ 10.3m
Manmohan Mahajan	Executive VP & Global CFO	less than a year	US$1.83m	0.019% $ 2.6m
Ornella Barra	Chief Operating Officer of International	no data	US$5.43m	0.24% $ 31.9m
Timothy Wentworth	CEO & Director	less than a year	no data	0.068% $ 9.2m
Todd Heckman	Senior VP	less than a year	no data	0.0010% $ 135.4k
Neal Sample	Executive VP & Chief Information Officer	less than a year	no data	no data
Tiffany Kanaga	Vice President of Global Investor Relations	no data	no data	no data
Matthew D'Ambrosio	Senior VP and Global Chief Compliance & Ethics Officer	no data	no data	no data
Lanesha Minnix	Executive VP & Global Chief Legal Officer	less than a year	no data	no data
Elizabeth Burger	Executive VP & Chief Human Resources Officer	no data	no data	no data
Liyue Wu	Head of M&A - Asia	no data	no data	no data
Tracey Brown	Executive VP	2.6yrs	no data	0.0030% $ 407.7k

0.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 0LSZ's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Stefano Pessina	Executive Chairman of the Board	12.2yrs	US$7.57m	0.076% $ 10.3m
Timothy Wentworth	CEO & Director	less than a year	no data	0.068% $ 9.2m
Ginger Graham	Lead Independent Director	14.2yrs	US$366.85k	0.00025% $ 33.9k
Valerie Jarrett	Independent Director	3.7yrs	US$300.00k	0.00052% $ 70.4k
Nancy Schlichting	Independent Director	17.7yrs	US$319.97k	0% $ 0
John Lederer	Independent Director	9.2yrs	US$315.00k	0.0058% $ 785.6k
Bryan Hanson	Independent Director	1.7yrs	US$84.62k	0.0011% $ 151.7k
Janice Babiak	Independent Director	12.2yrs	US$325.00k	0.00014% $ 19.0k
Inderpal Bhandari	Independent Director	1.8yrs	US$115.29k	0.00035% $ 47.4k
Thomas Polen	Director	less than a year	US$14.13k	0.00020% $ 27.1k
Robert Huffines	Independent Director	less than a year	no data	no data

3.7yrs

Average Tenure

66yo

Average Age

Experienced Board: 0LSZ's board of directors are considered experienced (3.7 years average tenure).

Walgreens Boots Alliance Management

Management criteria checks 1/4

Key information

Recent management updates

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Recent updates

Walgreens Boots Alliance, Inc. to Report Q3, 2024 Results on Jun 27, 2024

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

Second quarter 2024 earnings released: US$6.85 loss per share (vs US$0.81 profit in 2Q 2023)

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought US$340k worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold US$661k worth of stock

Upcoming dividend of US$0.48 per share

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. Names Alethia Jackson Senior Vice President, ESG and Chief DEI Officer

Walgreens Boots Alliance, Inc. Announces Resignation of David J. Brailer as Member of the Board of Directors

Upcoming dividend of US$0.48 per share

Jnd Legal Administration Announces A Class Action Lawsuit in the U.S. District Court for the District of Arizona Against Defendants Theranos, Inc., Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company

Walgreens Boots Alliance Increases Quarterly Dividend, Payable September 9, 2022

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$1.28 in 3Q 2021)

Walgreens Boots Alliance Concludes Strategic Review and Decides to Retain Ownership of Its Successful Boots Business

Walgreens Launches Clinical Trial Business to Address Industrywide Access and Diversity Challenges and Redefine Patient Experience

Walgreens Boots Alliance, Inc. to Report Q3, 2022 Results on Jun 30, 2022

Walgreens Reportedly Gives A Few Extra Days for Bidders to Firm Up Offers

An unknown buyer acquired 2.9% stake in AmerisourceBergen Corporation (NYSE:ABC) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $900 million.